Showing 2011-2020 of 3038 results for "".
- Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-positive-topline-results-for-its-seecase-phase-2-trial-of-nov03-for-the-treatment-of-patients-with-dry-eye-disease/2479732/Novaliq announces positive topline results for its SEECASE phase 2 clinical trial of NOV03 for the treatment of dry eye disease (DED) in more than 300 patients. NOV03 (100% perfluorohexyloctane) is a preservative-free ophthalmic solution and the first drug developed to treat evaporative DE
- Compact Imaging Collaborates with Novartis to Accelerate Development of Home Monitor for AMD and DRhttps://modernod.com/news/compact-imaging-collaborates-with-novartis-to-accelerate-development-of-home-monitor-for-amd-and-dr/2479735/Compact Imaging (CI), a developer of miniaturized optical coherence tomography (OCT) devices, announced the signing of a collaboration agreement with Novartis Pharma under which Novartis will fund Compact Imaging’s development of a low-cost home-based monitor to detect disease progression in adva
- Clerio Vision: First Noninvasive Laser Vision Correction Procedures Performedhttps://modernod.com/news/clerio-vision-first-noninvasive-laser-vision-correction-procedures-performed/2479743/Leveraging technology developed at the University of Rochester that was recently recognized with a Nobel Prize, Clerio Vision is commercializing LIRIC—a novel, noninvasive method to correct human vision. The core technology has been in development for more than 15 year
- Eylea Meets Main Goals in Phase 3 Non-Proliferative Diabetic Retinopathy Studyhttps://modernod.com/news/eylea-injection-improves-diabetic-retinopathy-and-reduces-vision-threatening-complications-in-phase-3-trial/2479745/Regeneron Pharmaceuticals announced that the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR) met its 1-year (52-week) primary endpoint and key secondary endpoints. On the primary end
- Non-Contact Panretinal Photocoagulation for Navilas 577s Introduced at AAO 2018https://modernod.com/news/non-contact-panretinal-photocoagulation-for-navilas-577s-introduced-at-aao-2018/2479753/At the AAO 2018 meeting in Chicago, OD-OS is launching a new widefield objective which brings non-contact panretinal photocoagulation with access to the far periphery (ora serrata) to the Navilas 577s Laser System. The new option for peripheral treatments can further enhance compliance of sensiti
- Johnson & Johnson Vision Appoints Carol Alexander, OD, Head, North America Vision Care Professional Relationshttps://modernod.com/news/johnson-johnson-vision-appoints-carol-alexander-od-head-north-america-vision-care-professional-relations/2479774/Carol Alexander, OD, has been appointed Head, North America Vision Care Professional Relations for Johnson & Johnson Vision. In this role, Carol will work to strengthen the relationship between Johnson & Johnson Vision and the optometric community in the US, w
- EyePoint Pharmaceuticals Receives FDA Approval of Yutiq for Chronic Noninfectious Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-receives-fda-approval-of-yutiq-for-noninfectious-uveitis/2479787/EyePoint Pharmaceuticals announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Yutiq utilizes the company’s Durasert drug delivery technology and is a non-bioerodible i
- Novaliq Raises New Capital to Accelerate the Commercialization of its Lead Products for Dry Eye Diseasehttps://modernod.com/news/novaliq-raises-new-capital-to-accelerate-the-commercialization-of-its-lead-products-for-dry-eye-disease/2479793/Novaliq announced it has raised $53 million to further support its late-stage products and earlier pipeline programs. Since inception, Novaliq has raised $115 million. The new investment is done by its lead investor dievini Hopp BioTech Holding, an active investor in Life and Health Scienc
- NovaBay Pharmaceuticals Names Jack McGovern Interim CEOhttps://modernod.com/news/novabay-pharmaceuticals-names-jack-mcgovern-interim-ceo/2479833/NovaBay Pharmaceuticals announced that Jack McGovern has been named interim Chief Executive Officer, expanding his responsibilities as Chief Financial Officer to include overseeing daily operations. Mark M. Sieczkarek, the company’s previous CEO, remains NovaBay’s Chairman and will focus on strat
- Novartis to File for New Lucentis (Ranibizumab) Indication in Retinopathy of Prematurity (ROP)https://modernod.com/news/novartis-to-file-for-new-lucentis-ranibizumab-indication-in-retinopathy-of-prematurity-rop/2479845/Novartis announced results from a phase 3 study of Lucentis (ranibizumab) versus laser surgery (the current standard of care) in premature infants with retinopathy of prematurity (ROP). Unlike laser surgery, which damages eye tissue and can be associated with significant complications such as hig